Emerging Infectious Disease ISSN: 1080-6059

Spread of Cryptococcus gattii in British Columbia, Canada, and Detection in the Pacific Northwest, USA

Laura MacDougall*

, Sarah E. Kidd†, Eleni Galanis*, Sunny Mak*, Mira J. Leslie‡, Paul R. Cieslak§, James W. Kronstad†, Muhammad G. Morshed*, and Karen H. Bartlett†

Author affiliations: *British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada; †University of British Columbia, Vancouver, British Columbia, Canada; ‡Washington State Department of Health, Shoreline, Washington, USA; §Oregon State Public Health, Portland, Oregon, USA;

Main Article

Figure 4

URA5–restriction fragment length polymorphism (RFLP) profiles for selected human, animal, and environmental Cryptococcus gattii isolates. A) URA5-RFLP to determine the molecular type using Hha I and Sau96 I endonucleases (14). B) URA5-RFLP to confirm molecular type and determine VGII subtype, using Hha I, Dde I, and BsrG I endonucleases.

Figure 4. URA5–restriction fragment length polymorphism (RFLP) profiles for selected human, animal, and environmental Cryptococcus gattii isolates. A) URA5-RFLP to determine the molecular type using Hha I and Sau96 I endonucleases (14). B) URA5-RFLP to confirm molecular type and determine VGII subtype, using Hha I, Dde I, and BsrG I endonucleases.

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.